Abstract: Objective：To evaluate the safety and primary outcome of stereotactic body radiation therapy(SBRT) for the consolidation treatment in patients with residual hepatocellular carcinoma after transarterial chemoembolization(TACE). Methods：From December 2012 to December 2015, clinical data of sixteen patients with hepatocellular carcinoma who received TACE combination with SBRT in Zhongshan Hospital affiliated to Fudan University were analyzed retrospectively. The median age was 55 years (range 4180 years),and the residual tumor was single (the median diameter was 2.8 cm).All cases were performed by 4dimensional CT positioning, showing the visible residual tumor lesions. Image guidedradiation therapy was used, total irradiation doses ranged from 48 Gy to 50 Gy in 5 to 10 fractions, and the supportive treatment was administrated during SBRT. Tumor responses were evaluated using the modified Response Evaluation and Criteria in Solid Tumors (mRECIST). Results：All of 16 cases completed SBRT. Based on mRECIST, 9 patients (56.3%) achieved complete response (CR), 6 cases (37.5%) achieved partial response (PR), but there were 1 patient (6.25%) with stable disease (SD)and no patient with progressive disease (PD) in radiation field. The overall objective response rate (CR+PR) was 93.8%. The overall survival (OS) rate at 1, 2, and 3 years was 100%, 93.6% and 93.6%, respectively. No radiationinduced liver disease was appeared. Conclusions：SBRT is safety and effective to treat patients with residual hepatocellular carcinoma after TACE. TACE combination with SBRT, as an effective combination for the treatment of advanced liver cancer, is worthy of further study.